MOR - Why Is Cancer Focused MorphoSys Stock Trading Lower Today? | Benzinga
MorphoSys AG (NASDAQ: MOR) released topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
Myelofibrosis causes extensive scarring in the bone marrow, leading to severe anemia. Bone marrow scarring can also cause a low number of blood-clotting cells called platelets, which increases the risk of bleeding. Myelofibrosis often causes an enlarged spleen (acts like a blood filter).
The study met its primary endpoint, as the ...